MEF2 signaling and human diseases

Xiao Chen; Bing Gao; Murugavel Ponnusamy; Zhijuan Lin; Jia Liu

doi:10.18632/oncotarget.22899

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

MEF2 signaling and human diseases

Xiao Chen, Bing Gao, Murugavel Ponnusamy, Zhijuan Lin and Jia Liu _

PDF | HTML | How to cite

Oncotarget. 2017; 8:112152-112165. https://doi.org/10.18632/oncotarget.22899

Metrics: PDF 2274 views | HTML 5191 views | ?

Abstract

Xiao Chen1,2,*, Bing Gao1,3,*, Murugavel Ponnusamy2, Zhijuan Lin2 and Jia Liu1,3

1School of Pharmacy, Qingdao University, Qingdao 266021, China

2Institute for Translational Medicine, Qingdao University, Qingdao 266021, China

3School of Basic Medicine, Qingdao University, Qingdao 266021, China

*These authors have contributed equally to this work

Correspondence to:

Jia Liu, email: [email protected]

Keywords: MEF2; human diseases; signaling pathway; microRNAs

Received: February 17, 2017 Accepted: September 09, 2017 Published: December 04, 2017

ABSTRACT

The members of myocyte Enhancer Factor 2 (MEF2) protein family was previously believed to function in the development of heart and muscle. Recent reports indicate that they are also closely associated with development and progression of many human diseases. Although their role in cancer biology is well established, the molecular mechanisms underlying their action is yet largely unknown. MEF2 family is closely associated with various signaling pathways, including Ca²⁺ signaling, MAP kinase signaling, Wnt signaling, PI3K/Akt signaling, etc. microRNAs also contribute to regulate the activities of MEF2. In this review, we summarize the known molecular mechanism by which MEF2 family contribute to human diseases.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22899

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

MEF2 signaling and human diseases

Abstract